| 2015-09 |
Niemann-Pick type C2 protein regulates liver cancer progression via modulating ERK1/2 pathway: Clinicopathological correlations and therapeutical implications |
International Journal of Cancer. 2015 Sep;137(6):1341-1351. |
 |
| 2007-09-01 |
Nighttime sleep, chinese afternoon nap, and mortality in the elderly |
Sleep. 2007 Sep;30(9):1105-1110. |
|
| 2018-11-22 |
Nile tilapia derived antimicrobial peptide TP4 exerts antineoplastic activity through microtubule disruption |
Marine Drugs. 2018 Nov 22;16(12):Article number 462. |
|
| 2010-10 |
Nilotinib and sorafenib are more potent inhibitors for exon 11/17 C-kit mutants than sunitinib: results of incorporating cell-based screening platform and virtual molecular modeling study |
Annals of Oncology. 2010 Oct;21(Suppl. 8):56-56. |
|
| 2009-01 |
Nitrate in drinking water and risk of death from pancreatic cancer in Taiwan |
Journal of Toxicology and Environmental Health Part A: Current Issues. 2009 Jan;72(6):397-401. |
|
| 2011-05 |
Nitrates in drinking water and the risk of death from brain cancer: Does hardness in drinking water matter? |
Journal of Toxicology and Environmental Health Part A: Current Issues. 2011 May;74(12):747-756. |
|
| 2011-05 |
Nitrates in drinking water and the risk of death from childhood brain tumors in Taiwan |
Journal of Toxicology and Environmental Health Part A: Current Issues. 2011 May;74(12):769-778. |
|
| 2010 |
Nitrates in drinking water and the risk of death from rectal cancer: does hardness in drinking water matter? |
Journal of Toxicology and Environmental Health Part A: Current Issues. 2010;73(19):1337-1347. |
|
| 2009-12 |
Nitrates in municipal drinking water and non-hodgkin lymphoma: An ecological cancer case-control study in Taiwan |
Journal of Toxicology and Environmental Health Part A: Current Issues. 2009 Dec;73(4):330-338. |
|
| 2011-12 |
Nitrite-Mediated S-Nitrosylation of Caspase-3 prevents hypoxia-induced endothelial barrier dysfunction |
Circulation Research. 2011 Dec;106(12):1375-1386. |
|
| 2024-07 |
Nitrogen and sulfur doped carbon dots coupled cellulose nanofibers: A surface functionalized nanocellulose membranes for air filtration |
Journal of the Taiwan Institute of Chemical Engineers. 2024 Jul;160:Article number 105324. |
|
| 2021-04-04 |
Nitrogen-doped titanium dioxide mixed with calcium peroxide and methylcellulose for dental bleaching under visible light activation |
International Journal of Molecular Sciences. 2021 Apr 4;22(7):Article number 3759. |
|
| 2017-02 |
Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial |
Journal of Clinical Oncology. 2017 Feb;35(4, Suppl.):2. |
|
| 2017-12 |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial |
Lancet. 2017 Dec;390(10111):2461-2471. |
|
| 2021-07 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab |
Gastric Cancer. 2021 Jul;24(4):946-958. |
|
| 2024-08-20 |
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri |
Gastric Cancer. 2024 Aug 20;Article in Press. |
|
| 2020-09 |
Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study |
Annals of Oncology. 2020 Sep;31(Suppl. 4):S1192. |
|
| 2022-02 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial |
Lancet Oncology. 2022 Feb;23(2):234-247. |
|
| 2023-11 |
Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome |
Annals of Oncology. 2023 Nov;34(Suppl. 3):S1390. |
|
| 2021-07 |
Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma |
Annals of Oncology. 2021 Jul;32(Suppl. 3):S141-S141. |
|
| 2018-09 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials |
Oncology Research and Treatment. 2018 Sep;41(Suppl. 4):285-286. |
|
| 2018-02 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials |
Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 90. |
|
| 2018-05 |
Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials |
Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Abstract number e15127. |
|
| 2017-04-03 |
NMD Classifier: A reliable and systematic classification tool for nonsense-mediated decay events |
PLoS ONE. 2017 Apr 03;12(4):Article number e0174798. |
|
| 2023-05-30 |
NMDA receptor glycine binding site modulators for prevention and treatment of ketamine use disorder |
Pharmaceuticals. 2023 May 30;16(6):Article number 812. |
|
